Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs
- 15 May 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (10) , 4304-4315
Abstract
IC87114 [compound 1, (2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one)] is a potent PI3K inhibitor selective for the δ isoform. As predicted by molecular modeling calculations, rotation around the bond connecting the quinazolin-4(3H)-one nucleus to the o-tolyl is sterically hampered, which leads to separable conformers with axial chirality (i.e., atropisomers). After verifying that the aS and aR isomers of compound 1 do not interconvert in solution, we investigated how biological activity is influenced by axial chirality and conformational equilibrium. The aS and aR atropisomers of 1 were equally active in the PI3Kδ assay. Conversely, the introduction of a methyl group at the methylene hinge connecting the 6-amino-9H-purin-9-yl pendant to the quinazolin-4(3H)-one nucleus of both aS and aR isomers of 1 had a critical effect on the inhibitory activity, indicating that modulation of the conformational space accessible for the two bonds departing from the central methylene considerably affects the binding of compound 1 analogues to PI3Kδ enzyme.Keywords
This publication has 54 references indexed in Scilit:
- Atropisomer Control in Macrocyclic Factor VIIa InhibitorsJournal of Medicinal Chemistry, 2016
- Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF‐06463922) and Desmethyl CongenersAngewandte Chemie International Edition, 2016
- Enantiomeric Atropisomers Inhibit HCV Polymerase and/or HIV Matrix: Characterizing Hindered Bond Rotations and Target SelectivityJournal of Medicinal Chemistry, 2013
- Discovery and Characterization of Atropisomer PH‐797804, a p38 MAP Kinase Inhibitor, as a Clinical Drug CandidateChemMedChem, 2011
- Assessing Atropisomer Axial Chirality in Drug Discovery and DevelopmentJournal of Medicinal Chemistry, 2011
- Revealing Atropisomer Axial Chirality in Drug DiscoveryChemMedChem, 2011
- The Challenge of Atropisomerism in Drug DiscoveryAngewandte Chemie International Edition, 2009
- Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs and manXenobiotica, 2003
- Stereochemical aspects of drug action and disposition1996
- Recent Advances in Atropisomerism1983